Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Clinical trial NCT04303130 · UNKNOWN
Trial details
- NCT number
- NCT04303130
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-31
- Primary completion
- 2022-12-31
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.